Des became Chief Executive Officer of OncoMark in July 2015. He has over 20 years’ experience in the Diagnostics industry with both early stage start-ups and international Corporations. He was Chief Operating Officer and Executive Director of Biotrin International from its establishment in the early 1990's through to its acquisition by Diasorin Corporation in 2008. During this time, Des oversaw the development and commercialization of over 15 new diagnostic tests, two of which (for Parvovirus B19) achieved FDA Pre-Market Approval and captured 70% of the worldwide market, with annual sales in excess of €10M. He also oversaw the development and launch of a number of Biomarker Tests for Kidney and Liver disease, which have applications in toxicity screening and clinical diagnoses.
Subsequent to the sale of Biotrin to Diasorin, Des became Managing Director of Diasorin Ireland (2009-2013), where he led the development of the Dublin site to become Diasorin's headquarters for their new Molecular diagnostics business in Infectious Disease and Oncology. He also held the position of Non-Executive Director at Argutus Medical, a Biomarker spin-out of Biotrin International, from 2008 until its acquisition by EKF Diagnostics in 2010.
Since 2013, Des has been active in the Medical Device Start-up sector. He participated in Enterprise Ireland's Business partner programme which facilitates the involvement of experienced entrepreneurs in the commercialization of academic research. He holds non-executive Directorships in two early stage start-ups operating in the Diagnostic and Medical Device sectors.
Des earned his M.I.Biol in Biochemistry at the Dublin Institute of Technology, his M.Sc. in Management at Trinity College, Dublin and recently completed a Diploma in Company Direction from the Institute of Directors in London.